Researchers found the oral antiviral drug nirmatrelvir/ritonavir (Paxlovid) is safe for kids as young as age 6 with mild/moderate COVID-19 who were at increased risk for severe disease, as published in Pediatrics. Of the in 75 children in the international study, 81% had 1 risk factor for severe COVID-19, most commonly obesity (49%) or chronic lung disease (40%). Additionally, 56% were unvaccinated. Children aged 6–17 years who weighed 40 kg or more received 300 mg …
Read More